Studies evaluating adjuvant chemotherapy after chemoradiation
| Author | Year | N | Adjuvant chemotherapy regimen | PFS (%) | OS (%) |
| Yavas70 | 2019 | 46 | Carboplatin/paclitaxel | 2 year: 93.5 | 95.7 |
| Angioli66 | 2015 | 95 | Cisplatin 4 courses Cisplatin 6 courses | 4 year: 80 4 year: 59.56 | 4 year: 84.21 4 year: 83.87 |
| Jelavic71 | 2015 | 118 | Cisplatin/ifosfamide | NR | 8 year: 74.6 |
| Tang64 | 2012 | 440 | Cisplatin/paclitaxel | 5 year: 71.4 | NR |
| Duenas-Gonzalez72 | 2012 | 259 | Cisplatin/gemcitabin | 3 year: 74.4 | 3 year: 78 |
| Kim73 | 2012 | 19 | Carboplatin/paclitaxel | 3 year: 62.7 | 3 year: 90.9 |
| Choi74 | 2011 | 39 | Cisplatin/5-FU | 70.1 | 92.7 |
| Zhang75 | 2010 | 34 | Paclitaxel/nedaplatin | 2 year: 82 | 2 year: 93 |
| Domingo76 | 2009 | 60 | Capecitabin | 1 year: 86 | 1 year: 95 |
| Choi77 | 2007 | 30 | Cisplatin/5-FU | 3 year: 83 | 3 year: 91 |
| Vrdoljak78 | 2006 | 62 | Cisplatin/Ifosfamide | 88.7 | 88.7 |
| Lorvidhaya62 | 2003 | 230 | 5-FU | 3 year: 63 5 year: 59.7 | 3 year: 79 5 year: 73.6 |
5-FU, 5-fluorouracil ; NR, not reported; OS, overall survival; PFS, progression free survival.